Gabapentin Capsule
Product Images NDC 76420-015

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76420-015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

A formula for calculating creatinine clearance (CLCr) is shown, involving age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier adjustment for female patients. This text appears related to dosage or pharmacokinetic information.*

FDA Label Image

1 (Image 10)

FDA Label Image

1 (Image 11)

FDA Label Image

1 (Image 13)

Gabapentin Capsules USP 100 mg packaging label showing a quantity of 30 capsules. Packaged by Enovachem Pharmaceuticals with address in Torrance, CA. Distributed by Actavis Pharma, Inc. The label includes the NDC 76420-014-30, barcode, lot number, batch number, and expiration date fields. Capsule described as white/light brown with logo.*

FDA Label Image

1 (Image 14)

Labels for Gabapentin Capsules USP 300mg by Enovachem Pharmaceuticals, packaged with quantities of 30, 60, 90, and 240 capsules. The labels display NDC numbers, distribution by Actavis Pharma, Inc., storage instructions, federal law caution, and a blue and white Enovachem logo with company address in Torrance, CA.*

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 5)

Chemical structure of Gabapentin shown as a hexagonal ring with attached amino (CH2NH2) and carboxymethyl (CH2CO2H) groups.*

FDA Label Image

1 (Image 6)

A line graph showing mean pain scores over an 8-week period comparing Gabapentin 3600 mg/day and placebo. The graph delineates a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a decrease in mean pain score over time compared to placebo.*

FDA Label Image

2 (Image 7)

A line graph depicting mean pain scores over a 7-week period, including a 3-week dose titration and a 4-week fixed dose period. It compares placebo with Gabapentin dosages of 1800 mg/day and 2400 mg/day, showing pain score trends from baseline through week 7.*

FDA Label Image

3 (Image 8)

This bar chart compares the percentage outcomes of two studies evaluating Gabapentin (GBP) at different dosages versus placebo (PBO). Study 1 compares PBO and GBP 3600 mg, showing higher percentages for GBP. Study 2 compares PBO, GBP 1800 mg, and GBP 2400 mg, with GBP groups showing higher percentages. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

4 (Image 9)

A scatter plot chart illustrating the percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis. It compares data points from three different studies labeled as STUDY a, STUDY b, and STUDY c, across daily doses ranging approximately from 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.